Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Arrowhead Pharmaceuticals raises $700 million in convertible notes
January 12, 2026 5:05 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) issued $700 million in convertible senior notes due 2032 on January 12, 2026, according to a company statement. The notes carry a 0.00% interest rate and do not accrete in principal amount.
J.P. Morgan Securities LLC and Jefferies LLC served as underwriters for the offering. The underwriters exercised their full over-allotment option to... More
